CHICAGO (Reuters) - Adding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage trial, the companies reported on Monday. | 08:21am
Experts say mRNA vaccines, paired with drugs that rev up the immune system, may lead to a new generation of cancer therapies. Read more at straitstimes.com.